🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Biotech startup Exsure raises seed round led by Unicorn India Ventures

EntrackrEntrackr · 9m ago
Biotech startup Exsure raises seed round led by Unicorn India Ventures
Medial

Biotech startup Exsure has raised Rs 3 crore in a seed round led by Unicorn India Ventures. The fresh funds will be used to complete the non-clinical study of its exosome-based drug delivery platform, support its global expansion plans with in-house manufactured R&D products, and promote its offerings, including Exosure, Leucosure, PlantExosure, and Dr. Berries, the company said in a press release. Co-founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure is a biotech startup focused on reducing the side effects and toxicity of anti-cancer drugs through its patented exosomal drug-delivery platform that targets both cancer and cancer stem cells. With its cutting-edge technology, the company aims to minimize the toxic effects of chemotherapy and reduce the likelihood of cancer relapse, thereby improving the quality of life for cancer patients. Over the past 12 months, Exsure has initiated a non-clinical study in India in collaboration with a CRO and completed preclinical studies using its patented technology. The company has launched its first in-house manufactured products and gained collaborators and partners across India for its products and services. According to market research, the Indian biotechnology industry is expected to reach $150 billion by 2025 and has the potential to grow to $270–300 billion by 2030. The Bhubaneswar-based company reported fivefold growth in the last fiscal year and is on track to service more than 50 clients this year with its R&D products, including Exosure (a 3-in-1 exosome isolation reagent), Leucosure (a PBMC isolation reagent), and PlantExosure (India’s first plant exosome isolation reagent). Additionally, the company has been selected for the OIST Innovation Accelerator Program in Japan to support its business expansion and conduct clinical trials.

1

Related News

Genexis Biotech raises Rs 4 Cr in seed round led by GVFL

EntrackrEntrackr · 3m ago
Genexis Biotech raises Rs 4 Cr in seed round led by GVFL
Medial

Genexis Biotech raises Rs 4 Cr in seed round led by GVFL Vadodara-based bio-manufacturing startup Genexis Biotech has raised Rs 4 crore in a seed funding round led by GVFL, with participation from Benzai10. The proceeds will be used to scale bioreactor capacity, build downstream processing infrastructure, launch new recombinant proteins and enzymes, and strengthen compliance, sales, and distribution functions. Genexis Biotech develops animal-origin-free recombinant proteins using precision fermentation, catering to sectors like biopharma, food-tech, and cell culture. The startup operates a certified Class 10,000 facility and is setting up a GMP-compliant unit. It has introduced recombinant peptidases such as amino peptidase and enterokinase, and plans to launch recombinant transferrin and albumin. In the past year, Genexis established partnerships with pharmaceutical companies and biotech firms, signed an MoU with the Gujarat government, and received client orders for alternative protein formulations. It showcased its portfolio at Global Bio-India 2024 and aims to enter the regulated biotech export market, develop encapsulated formulations for the cosmetics industry, and collaborate with CDMOs, academic labs, and biopharma firms. Genexis Biotech focuses on scalable, ethical biomolecule production. GVFL has backed the company as part of its investment thesis across deeptech and biotech innovation.

StampMyVisa raises Rs 4 Cr in bridge round led by Unicorn India Ventures

EntrackrEntrackr · 10h ago
StampMyVisa raises Rs 4 Cr in bridge round led by Unicorn India Ventures
Medial

Snippets StampMyVisa raises Rs 4 Cr in bridge round led by Unicorn India Ventures B2B visa processing platform StampMyVisa (SMV) has raised Rs 4 crore in a bridge round led by existing investor Unicorn India Ventures (UIV). The fresh capital will be used for growth, marketing and to support the company’s recent acquisition of Kunal Shah backed Teleport, which expands its operations in South India. Unicorn India Ventures had earlier invested Rs 6.6 crore in StampMyVisa during its seed round last year. The company aims to use this bridge round to achieve key milestones before raising a larger Series A round in the next financial year. StampMyVisa said it has achieved 4 times growth in revenue while maintaining a 99.5% visa success rate, processing more than 75,000 visas in the past six months. Its proprietary AI engine Nucleus automates and validates visa documentation for over 80 countries. The company recently introduced new products including SMV Insure, which refunds the booking value if a visa is rejected, and SMV Global, an eSIM service offering international connectivity at lower cost than regular roaming. It plans to expand into GCC markets and build fintech infrastructure with embedded credit and payment solutions for small and medium businesses. The platform targets to process 80% of visa applications within five minutes, compared to the current industry average of two days. In August 2025, StampMyVisa acquired travel tech startup Teleport, a consumer facing player backed by founders including Kunal Shah, Vidit Aatrey and Phanindra Sama. It competes with Atlys, Visa2Fly and StampThePassport.

Download the medial app to read full posts, comements and news.